Company Overview - Huasheng Technology (SZ 000790) announced its 16th meeting of the 13th Board of Directors on November 14, 2025, where it reviewed the proposal to amend the company's articles of association [1] Financial Performance - For the first half of 2025, Huasheng Technology's revenue composition was as follows: Pharmaceuticals accounted for 78.26%, health services for 17.99%, other businesses for 2.57%, construction steel structures for 1.06%, and medical devices for 0.12% [1] Market Capitalization - As of the report, Huasheng Technology's market capitalization stood at 2.8 billion yuan [1]

成都华神科技集团股份有限公司 公司章程 成都华神科技集团股份有限公司 Chengdu huasun technology group Inc., LTD. 1 | 第一章 总则. | | --- | | 第二章 经营宗旨和范围 . | | 第三章 股份 | | 第四章 股东和股东会 b | | 第五章 董事和董事会 | | 第六章 高级管理人员 . | | 第七章 财务会计制度、利润分配和审计 33 | | 第八章 通知和公告 | | 第九章 合并、分立、增资、减资、解散和清算 39 | | 第十章 修改章程 | | 第十一章 附则 | 第一章 总则 第一条 为维护成都华神科技集团股份有限公司（以下简称"公司"）、股东、职工和债 权人的合法权益，规范公司的组织和行为，根据《中华人民共和国公司法》（以下简称《公司 法》）、《中华人民共和国证券法》（以下简称《证券法》）和其他有关规定，制订本章程。 第二条 公司系依照四川省人民政府《关于超前试点改革的决定》和其他有关规定成立的 股份有限公司。公司经成都市体改委成体改（1988）009 号文《关于同意组建成都建业发展股 份有限公司的批复》批准，以发起方式设立；在成都 ...

成都华神科技集团股份有限公司 《公司章程》修订对照表（2025 年 11 月） 根据《公司法》《上市公司章程指引》等相关法律法规、规范性文件的最 新规定及有关工商管理部门的要求，结合公司实际情况，公司拟对《公司章 程》相关条款进行修订。具体内容如下： | 依法承担连带责任。 | 民法院提起诉讼。 | | --- | --- | | | 公司董事会不按照本条第一款的规定执行的，负有责任 | | | 的董事依法承担连带责任。 | | 第一节 股东 | 第一节 股东的一般规定 | | 第三十条 公司依据证券登记机构提供的凭证建立股东名 | 第三十一条 公司依据证券登记结算机构提供的凭证建 | | 册，股东名册是证明股东持有公司股份的充分证据。股东 | 立股东名册，股东名册是证明股东持有公司股份的充分 | | 按其所持有股份的种类享有权利，承担义务；持有同一种 | 证据。股东按其所持有股份的类别享有权利，承担义务 | | 类股份的股东，享有同等权利，承担同种义务。 | ；持有同一类别股份的股东，享有同等权利，承担同种 | | | 义务。 | | 第三十二条 公司股东享有下列权利： | 第三十三条 公司股东享有下列权利 ...

证券代码：000790 证券简称：华神科技 公告编号：2025-047 成都华神科技集团股份有限公司 关于召开 2025 年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 经成都华神科技集团股份有限公司（以下简称"公司"）第十三届董事会第二十六次 会议审议决定，公司将以现场表决与网络投票相结合的方式召开2025年第二次临时股东 会。现将有关事项通知如下： 一、召开会议的基本情况 1、股东会届次 成都华神科技集团股份有限公司2025年第二次临时股东会 2、股东会的召集人 董事会 3、会议召开的合法、合规性 本次股东会的召集、召开符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》的规定。 2025年12月2日（星期二）14:30。 （2）网络投票时间 2025年12月2日，其中，通过深圳证券交易所交易系统进行网络投票的时间为：2025 年12月2日9:15--9:25，9:30--11:30，13:00--15:00；通过深圳证券交易所互联网投票系统 投票的时间为：2025年12月2日9:15至15:00期间的任意时间。 5、会议 ...

证券代码：000790 证券简称：华神科技 公告编号：2025-046 成都华神科技集团股份有限公司 第十三届董事会第二十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 成都华神科技集团股份有限公司（简称"公司"）第十三届董事会第二十六 次会议于2025年11月14日以通讯表决的方式在公司会议室召开，经与全体董事 沟通确认，全体董事同意豁免本次董事会会议的提前通知期限，本次会议通知 于2025年11月14日发出，本次会议应出席董事9人，实际出席董事9人。会议由 公司董事长黄明良先生主持，公司监事、高级管理人员列席了会议。本次会议 的召集、召开符合有关法律、行政法规、部门规章、规范性文件和《公司章 程》的有关规定。 二、董事会会议审议情况 根据相关法律法规、规范性文件的最新规定及有关工商管理部门的要求， 公司在2025年10月29日召开的第十三届董事会第二十五次会议审议通过的《公 司章程》的基础上进行了修订。具体内容详见公司同日在巨潮资讯网披露的相 关文件。本议案尚需提交股东会审议。 表决结果：同意9票，反对0票，弃权0 ...

证券之星消息，11月13日中药板块较上一交易日上涨0.24%，盘龙药业领涨。当日上证指数报收于 4029.5，上涨0.73%。深证成指报收于13476.52，上涨1.78%。中药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 002864 | 盘龙药业 | 39.20 | 9.99% | 23.77万 | | 8.64亿 | | 000790 | 华神科技 | 4.54 | 5.09% | 52.49万 | | 2.36 Z | | 600222 | 太龙药业 | 7.90 | 4.91% | 79.34万 | | 6.10亿 | | 002728 | 特一药业 | 13.83 | 3.13% | 142.97万 | | 18.94亿 | | 301331 | 恩威医药 | 32.62 | 2.68% | 3.31万 | | 1.07亿 | | 600080 | 金花股份 | 8.50 | 2.41% | 39.37万 | | 3.27亿 | | 00260 ...

Core Insights - The Chinese medicine market is experiencing rapid growth, driven by favorable policies and increasing market demand, as highlighted by the recent 12th World Traditional Chinese Medicine Conference held in Sydney, Australia [1][2]. Group 1: Market Performance - As of November 10, 2025, the Zhongzheng Traditional Chinese Medicine Index (930641) rose by 1.11%, with notable increases in stocks such as Zhongsheng Pharmaceutical (002317) up 3.69% and Kangyuan Pharmaceutical (600557) up 3.22% [1]. - The Traditional Chinese Medicine ETF (159647) increased by 0.88%, with the latest price reported at 1.03 yuan [1]. Group 2: Industry Growth Drivers - The conference attracted over 800 representatives from 24 countries, emphasizing the global interest in the dissemination and technological innovation of traditional Chinese medicine [1]. - Pacific Securities notes that the industry is supported by comprehensive measures across supply, payment, and demand sides, including registration, review, quality control, and cultural promotion [1]. Group 3: Key Constituents - As of October 31, 2025, the top ten weighted stocks in the Zhongzheng Traditional Chinese Medicine Index accounted for 54.92% of the index, including major players like Yunnan Baiyao (000538) and Tongrentang (600085) [2].

Group 1 - The core point of the news is that Huasheng Technology's stock price increased by 6.14% to 4.32 CNY per share, with a trading volume of 88.1 million CNY and a turnover rate of 3.39%, resulting in a total market capitalization of 2.694 billion CNY [1] - Huasheng Technology, established on January 27, 1988, and listed on March 27, 1998, is primarily engaged in the research, production, and sales of traditional Chinese and Western medicines, as well as biopharmaceuticals and steel structure construction [1] - The revenue composition of Huasheng Technology includes 78.26% from traditional Chinese and Western medicines, 17.99% from health drinks and services, 2.57% from other sources, 1.06% from steel structure manufacturing and installation services, and 0.12% from medical devices [1] Group 2 - Among the top ten circulating shareholders of Huasheng Technology, a fund under Huatai-PineBridge is the largest shareholder, having increased its holdings by 1.0127 million shares to a total of 3.886 million shares, representing 0.62% of the circulating shares [2] - The Huatai-PineBridge Zhongzheng Traditional Chinese Medicine ETF (560080) was established on September 26, 2022, with a latest scale of 2.489 billion CNY, and has experienced a loss of 0.83% this year, ranking 4160 out of 4216 in its category [2] - The fund has incurred a loss of 4.25% over the past year, ranking 3840 out of 3913, while achieving a return of 8.25% since its inception [2]

Core Viewpoint - Huasheng Technology, a well-known pharmaceutical company in China, focuses on the research and development of traditional Chinese medicine and biopharmaceuticals, but its financial performance lags behind industry leaders [1][2]. Financial Performance - In Q3 2025, Huasheng Technology reported revenue of 457 million yuan, ranking 57th among 69 companies in the industry, significantly lower than the top performer, Baiyunshan, with 61.606 billion yuan, and Yunnan Baiyao at 30.654 billion yuan [2]. - The company's net profit for the same period was -97.1142 million yuan, placing it 64th in the industry, while Yunnan Baiyao and Baiyunshan reported net profits of 4.789 billion yuan and 3.398 billion yuan, respectively [2]. Financial Ratios - As of Q3 2025, Huasheng Technology's debt-to-asset ratio was 48.98%, slightly higher than the previous year's 48.94% and above the industry average of 32.81% [3]. - The gross profit margin for the same period was 45.48%, down from 47.92% year-on-year and below the industry average of 52.44% [3]. Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 5.50% to 37,000, while the average number of circulating A-shares held per account increased by 5.82% to 16,800 [5]. - Among the top ten circulating shareholders, Huatai-PB Zhongzheng Chinese Medicine ETF ranked eighth with 3.886 million shares, an increase of 1.0127 million shares from the previous period [5]. Executive Compensation - The chairman of Huasheng Technology, Huang Mingliang, received a salary of 799,700 yuan in 2024, an increase of 210,800 yuan compared to 588,900 yuan in 2023 [4].

Core Viewpoint - Huasheng Technology (000790.SZ) reported a significant decline in revenue and net profit for the first three quarters of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved an operating income of 457 million yuan, representing a year-on-year decrease of 31.02% [1] - The net profit attributable to shareholders of the listed company was -97.7853 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -72.1513 million yuan [1] - The basic earnings per share were -0.1568 yuan [1]